Insulin delivery route for the artificial pancreas: Subcutaneous, intraperitoneal, or intravenous? Pros and cons

Journal of Diabetes Science and Technology

Volumn 2, Issue 4, 2008, Pages 735-738

  Renard, Eric ^a,b  

^a LAPEYRONIE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Artificial pancreas; Closed loop control; Insulin delivery

Indexed keywords

EID: 77954067827     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200429     Document Type: Conference Paper

References (29)

1. Renard E. Implantable closed loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr Opin Pharmacol. 2002;2(6):708-16.
2. Klonoff DC. The artificial pancreas: how sweet engineering will solve bitter problems. J Diabetes Sci Technol. 2007;1(1):72-81.
3. Albisser AM, Leibel BS, Ewart TF, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R. Clinical control of diabetes by the artificial pancreas. Diabetes. 1974;23(5):397-404.
4. Mirouze J, Selam JL, Pham TC, Cavadore D. Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulindependent diabetes. Diabetologia. 1977;13(3):273-8.
5. Selam JL, Charles MA. Devices for insulin administration. Diabetes Care. 1990;13(9):955-79.
6. Blackshear PJ, Shulman GI, Roussell AM, Nathan DM, Minaker KL, Rowe AM, Robbins DC, Cohen AM. Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. J Clin Endocrinol Metab. 1985;61(4):753-60.
7. Selam JL, Micossi P, Dunn FL, Nathan DM. Clinical trial of programmable implantable insulin pumps for type 1 diabetes. Diabetes Care. 1992;15(7):877-85.
8. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29) ]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43(3):396-402.
9. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care. 1998;21(6):977-82.
10. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23(1):1-12.
11. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-50.
12. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane W V. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-9. Epub 2008 Feb. 5.
13. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin deliverythe path to physiological glucose control. Adv Drug Deliv Rev. 2004;56(2):125-44.
14. Zisser H, Jovanovic L. OmniPod insulin management system: patient perceptions, preference, and glycemic control. Diabetes Care. 2006;29(9):2175.
15. Botz CK, Leibel BS, Zingg W, Gander RE, Albisser AM. Comparison of peripheral and portal routes of insulin infusion by a computercontrolled insulin infusion system (artificial endocrine pancreas). Diabetes. 1976;25(8):691-700.
16. Giacca A, Caumo A, Galimberti G, Petrella G, Librenti MC, Scavini M, Pozza G, Micossi P. Peritoneal and subcutaneous absorption of insulin in type 1 diabetic subjects. J Clin Endocrinol Metab. 1993;77(3):738-42.
17. Nathan DM, Dunn FL, Bruch J, McKitrick C, Larkin M, Haggan C, Lavin-Tompkins J, Norman D, Rogers D, Simon D. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. Am J Med. 1996;100(4):412-7.
18. Saudek CD, Selam JL, Pitt HA, Waxman K, Rubio M, Jeandidier N, Turner D, Fischell RE, Charles MA. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321(9):574-9.
19. Hanaire-Broutin H, Broussolle C, Jeandidier N, Renard E, Guerci B, Haardt MJ, Lassmann-Vague V. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Diabetes Care. 1995;18(3):388-92.
20. Catargi B, Meyer L, Melki V, Renard E, Jeandidier N; for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab. 2002;28(2):133-7.
21. Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicentre experience with implantable insulin pumps. The EVADIAC Study Group. Lancet. 1994;343(8896):514-5.
22. Selam JL, Raymond M, Jacquemin JL, Orsetti A, Richard JL, Mirouze J. Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. Diabetes Metab. 1985;11(3):170-3.
23. Oskarsson PR, Lins PE, Backman L, Adamson UC. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycemia in type 1 diabetic patients. Diabetes Metab. 2000;26(2):118-24.
24. Oskarsson PR, Lins PE, Wallberg-Henriksson H, Adamson UC. Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. Diabetes Metab. 1999;25(6):491-7.
25. Renard E, Bouteleau S, Jacques-Apostol D, Lauton D, Gibert-Boulet F, Costalat G, Bringer J, Jaffol C. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin-pump compatibility. Diabetes Care. 1996;19(8):812-7.
26. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes. 1982;41(9):1042-9.
27. Renard E, Costalat G, Chevassus H, Bringer J. Artificial beta cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab. 2006;32(5 Pt 2):497-502.
28. Renard E, Costalat G, Chevassus H, Bringer J. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract. 2006;74(Suppl 2):S173-7.
29. Olsen CL, Chan E, Turner DS, Iravani M, Nagy M, Selam JL, Wong ND, Waxman K, Charles MA. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care. 1994;17(3):169-76.